Claims for Patent: 8,772,306

Summary for Patent: 8,772,306

Title:	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Abstract:	One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
Inventor(s):	Eller; Mark (Redwood City, CA)
Assignee:	Jazz Pharmaceuticals, Inc. (Palo Alto, CA)
Application Number:	13/872,997
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,772,306
Patent Claims:	1. A method for treating a patient who is suffering from excessive daytime sleepiness, cataplexy, sleep paralysis, apnea, narcolepsy, sleep time disturbances, hypnagogic hallucinations, sleep arousal, insomnia, or nocturnal myoclonus with gamma-hydroxybutyrate (GHB) or a salt thereof, said method comprising: orally administering to the patient in need of treatment at least 5% decrease in an effective dosage amount of the GHB or salt thereof when the patient is receiving a concomitant administration of valproate, an acid, salt, or mixture thereof. 2. The method in accordance with claim 1, wherein there is at least about a 15% reduction in the effective dosage amount of the GHB or salt thereof given to the patient and wherein the valproate, acid, salt or mixture thereof is divalproex sodium. 3. The method in accordance with claim 2, wherein the dose of the GHB or salt thereof given to the patient without concomitant administration of valproate, an acid, salt or mixture thereof is from 4.5 to 9 grams per day. 4. The method in accordance with claim 1, wherein the effective dosage amount is a reduction of about 5% to 10%, about 10% to 15%, about 15% to 20%, about 20% to 25%, about 25% to 30%, about 30% to 35%, about 35% to 40%, about 40% to 45%, or about 45% to 50%, relative to the dose of the GHB or salt thereof normally given to the patient. 5. The method in accordance with claim 1, wherein the patient is suffering from narcolepsy. 6. The method in accordance with claim 1, further comprising administering aspirin to the patient. 7. The method in accordance with claim 1, wherein the effective dosage amount of the GHB or a salt thereof is reduced from a range of 4.5 to 9 grams per day. 8. The method in accordance with claim 1, wherein the dose of the GHB or salt thereof without concomitant administration of valproate, an acid, salt or mixture thereof is from 4.5 to 9 grams per day. 9. The method in accordance with claim 1, wherein the effective dosage amount of the GHB or salt thereof is between 3 grams and 7 grams per day. 10. The method in accordance with claim 1, wherein the effective dosage amount of the GHB or salt thereof is between 3.5 grams and 4 grams per day. 11. A method of safely administering GHB or a salt thereof for excessive daytime sleepiness, cataplexy, sleep paralysis, apnea, narcolepsy, sleep time disturbances, hypnagogic hallucinations, sleep arousal, insomnia, or nocturnal myoclonus in a human patient who is being administered GHB, said method comprising: determining if the patient has taken, or will take, a concomitant dose of valproate, an acid, salt or mixture thereof; and orally administering a reduced amount of the GHB or salt thereof to the patient wherein the reduction is at least 5% compared to a dose without concomitant administration of valproate, an acid, salt or mixture thereof. 12. The method in accordance with claim 11, wherein the amount of GHB or salt thereof is reduced at least 10% to 30%. 13. The method in accordance with claim 11, wherein the amount of GHB or salt thereof is reduced at least 15% patient and wherein the valproate, acid, salt, or mixture thereof is divalproex sodium. 14. The method in accordance with claim 11, wherein the valproate, acid, salt or mixture thereof is administered within two weeks of administration of the GHB or salt thereof. 15. The method in accordance with claim 11, wherein the valproate, acid, salt or mixture thereof is administered within three days of administration of the GHB or salt thereof. 16. The method in accordance with claim 11, wherein the patient is suffering from narcolepsy. 17. The method in accordance with claim 11, further comprising administering aspirin to the patient. 18. The method in accordance with claim 11, further comprising recommending to decrease the dose of GHB or salt thereof by 20% patient and wherein the valproate, acid, salt, or mixture thereof is divalproex sodium. 19. A method for treating a patient who is suffering from narcolepsy, said method comprising: administering a therapeutically effective amount of a formulation containing a GHB salt to a patient starting at a concentration of between 350 and 750 mg/ml with a pH of between 6 and 10; determining if the patient is also being administered valproate, an acid, salt or mixture thereof; warning of a potential drug/drug interaction due to the combination of valproate, an acid, salt or mixture thereof and the GHB salt; and recommending reducing the dose of the GHB salt at least 15%. 20. The method in accordance with claim 19, wherein the valproate, acid, salt or mixture thereof is administered within two weeks of administration of the GHB salt. 21. The method in accordance with claim 19, wherein the valproate, acid, salt or mixture thereof is administered within three days of administration of the GHB salt. 22. The method in accordance with claim 19, wherein the GHB salt is administered starting at a concentration of between 450 to 550 mg/ml. 23. The method in accordance with claim 22, further comprising adding water to the GHB salt formulation. 24. The method in accordance with claim 19, wherein the GHB salt formulation has a pH between 6.5 and 8. 25. The method in accordance with claim 19, further comprising administering the reduced dose of the GHB salt to the patient. 26. The method in accordance with claim 19, wherein the GHB salt comprises a single salt or a mixture of salts of GHB selected from the group consisting of a sodium salt of hydroxybutyrate (Na.GHB), a potassium salt of gamma-hydroxybutyrate (K.GHB), a magnesium salt of gamma-hydroxybutyrate (Mg.(GHB).sub.2), and a calcium salt of gamma-hydroxybutyrate (Ca.(GHB).sub.2). 27. The method in accordance with claim 19, further comprising administering aspirin to the patient. 28. The method in accordance with claim 19, comprising recommending reducing a dose of GHB or salt thereof at least 20% patient and wherein the valproate, acid, salt, or mixture thereof is divalproex sodium. 29. The method in accordance with claim 19, further comprising adding water to the GHB salt formulation. 30. A method for treating a patient who is suffering from narcolepsy, said method comprising: administering a therapeutically effective amount of a formulation containing a GHB salt to a patient; determining if the patient is also being administered valproate, an acid, salt or mixture thereof; recommending a 20% decrease in the starting dose of the GHB salt such that a patient starts taking the GHB salt at an adjusted dosage amount between 3.5 grams and 4 grams the GHB salt per night administered orally. 31. The method in accordance with claim 30, wherein the starting adjusted dosage amount of the GHB salt is about 3.6 grams. 32. The method in accordance with claim 30, further comprising optionally diluting the GHB salt formulation from a starting concentration of between 350 and 750 mg/ml with a pH of between 6 and 10. 33. A method for treating a patient who is suffering from narcolepsy, said method comprising: orally administering a therapeutically effective amount of a formulation containing a GHB salt; determining if the patient is also being administered valproate, an acid, salt or mixture thereof; recommending a 20% decrease in the starting dose of the GHB salt such that the amount that the patient is administered is reduced to about 3.6 grams GHB per day. 34. The method in accordance with claim 33, further comprising optionally diluting the GHB salt formulation from a starting concentration of between 350 and 750 mg/ml with a pH of between 6 and 10.